

Primary Squamous Cell Carcinoma of Thyroid – A Case Report with Emphasis on Treatment Options and Review of Literature

Gautam Vedagiri Vydia¹, Ramanaiah K¹, Aravind Krishnamoorthy², Sadanand S¹

¹Department of Radiation Oncology, Cancer Institute (WIA), Adyar, India. ²Department of Surgical Oncology, Cancer Institute (WIA), Adyar, India.

Abstract

Introduction: Primary squamous cell carcinoma of thyroid (PSCCT) is a rare entity with less than 100 cases reported in literature. It constitutes about 1% of all thyroid cancers. It has an aggressive behaviour and unfavourable prognosis. We report a rare case of PSCCT and provide a review of literature on PSCCT. **Case Report:** A 45 year old gentleman with hypertension as co morbid condition reported to our hospital with complaints of swelling in anterior part of the neck. He was diagnosed as a case of carcinoma of thyroid. He underwent Total Thyroidectomy under general anaesthesia. With histopathology and IHC correlation, diagnosed as PSCCT. He received adjuvant RT to tumor bed to a total dose of 60 Gray (Gy) over a period of 6 weeks. **Conclusion:** PSCCT is a very rare disease with very aggressive course. There is no consensus on the line of management. Lenvatinib can be tried in PSCCT as it resembles ATC.

Keywords: Primary squamous cell carcinoma of thyroid- review of literature- adjuvant radiotherapy- Lenvatinib

Asian Pac J Cancer Care, 10 (1), 369-371

Submission Date: 10/02/2024 Acceptance Date: 12/27/2024

Introduction

Primary squamous cell carcinoma of thyroid (PSCCT) is a rare entity with less than 100 cases reported in literature. It constitutes about 1% of all thyroid cancers [1]. It has an aggressive behaviour and unfavourable prognosis. The diagnosis can be challenging because of the presence of squamous metaplasia in other thyroid malignancies and direct extension into thyroid from locally aggressive squamous cell carcinoma (SCC) [2]. PSCCT can be diagnosed only after ruling out metastasis from other sites, local part imaging, surgical excision of thyroid and immunohistochemistry (IHC) analysis [3]. We report a rare case of PSCCT and provide a review of literature on PSCCT.

Case Report

A 45 year old gentleman with hypertension as co morbid condition reported to our hospital with complaints of swelling in anterior part of the neck. He had no other significant history like radiation exposure, family history of thyroid malignancies. Examination revealed a 3 x 3 cm hard swelling in left side of anterior neck. The swelling

was moving with deglutition. Multiple small nodes were felt in left level III region. Baseline blood investigations were done and were normal. Ultrasound neck was done at an outside hospital which showed an irregular hypoechoic solid mass in left lobe of thyroid. FNAC done at an outside hospital was suggestive of malignant neoplasm. He was diagnosed as a case of carcinoma of thyroid. He underwent Total Thyroidectomy under general anaesthesia. Post-operative period was uneventful. Immunohistochemistry (IHC) like keratin, CK 5/6, p40, CK 7, TTF -1, calcitonin, CEA, PAX 8, LMP, CD 21, LCA were requested on the surgical pathology specimen. IHC keratin, CK 5/6, p40, CK 7 showed positive reaction. IHC TTF -1, calcitonin, CEA, PAX 8, LMP, CD 21, LCA showed negative reaction. With histopathology and IHC correlation, diagnosed as PSCCT. Case was discussed in our hospital multidisciplinary board and he was planned for adjuvant radiotherapy (RT). He received adjuvant RT to tumor bed to a total dose of 60 Gray (Gy) using IMRT technique over a period of 6 weeks. No RT related morbidity was noted. He was kept under follow up.

Corresponding Author:

Dr. Gautam Vedagiri Vydia

Department of Radiation Oncology, Cancer Institute (WIA), Adyar, India.

Email: gautam.gv71@gmail.com

Discussion and Review of Literature

PSCCT is rare entity which accounts only for about 0.2 to 1 % of all thyroid malignancies. Aetiology is unknown. There are 3 theories proposed. First, Embryonic origin involving branchial arch or thyroglossal duct remnant. Second is the metaplastic transformations secondary to chronic inflammatory thyroiditis. Last is the dedifferentiation of other thyroid carcinomas [1, 4, 5]. The last theory has led a few to consider PSCCT as a variant of anaplastic carcinoma, although the association remains unclear. Females are affected more, with a median age of presentation in 5th and 6th decade of life [6]. Patients usually present with a mass in neck associated with compressive symptoms. IHC plays a critical role in diagnosing PSCCT and distinguishing it from others. IHC can be positive for epithelial markers like CK 5/6, CK 7 which would confirm squamous cell of origin. TTF 1 and thyroglobulin negativity will rule out other common thyroid malignancies. PAX 8 positivity will confirm primary thyroid aetiology [7-9]. Management of PSCCT remains unclear due to the rarity of disease. Mostly they have been treated with surgical resection followed by adjuvant radiotherapy. If found to be unresectable, then concurrent chemoradiation has been tried, though response is poor [4]. Cook et al, who had published the largest review on PSCCT, showed that patients who underwent complete surgery followed by adjuvant radiotherapy had a longer survival when compared with others who underwent surgical resection alone or others who had incomplete surgical resection [10]. It is still unclear whether multimodality treatment will be beneficial in patients with PSCCT [11]. Some authors suggest surgical resection with or without adjuvant radiation as the main stay of treatment [12]. Our patient was treated with complete surgical resection followed by adjuvant radiotherapy. In regard to systemic therapy, chemotherapy has been used to little or no response. It was reported that almost half of the patients with PSCCT had distant metastasis at presentation. Though conventional chemotherapy has not shown any survival benefit. Many published literature have shown better outcomes of anaplastic carcinoma of thyroid (ATC) when treated with lenvatinib. Lenvatinib is a tyrosine kinase inhibitor which selectively inhibits multiple angiogenic and oncogenic signal pathways. The evidence for lenvatinib comes from SELECT trial and phase II data on lenvatinib in ATC [13-15]. Though trials did not include PSCCT patients, lenvatinib can be used for PSCCT given the fact that it behaves like ATC. There is very limited literature on the use of lenvatinib in PSCCT.

In conclusion, PSCCT is a very rare disease with very aggressive course. Histopathology and IHC correlation help in differentiating PSCCT from other common thyroid malignancies. There is no consensus on the line of management, but given the aggressiveness of the disease, complete surgical resection followed by adjuvant radiotherapy should be given as it had improved survival based cook et al. Chemotherapy has limited role in PSCCT. Lenvatinib can be tried in PSCCT as it resembles ATC.

Larger prospective studies will be difficult given the rarity of the disease.

Acknowledgments

Statement of Transparency and Principals

- Author declares no conflict of interest
- Study was approved by Research Ethic Committee of author affiliated Institute.
- Study's data is available upon a reasonable request.
- All authors have contributed to implementation of this research.

References

1. Syed MI, Stewart M, Syed S, Dahill S, Adams C, McLellan DR, Clark LJ. Squamous cell carcinoma of the thyroid gland: primary or secondary disease?. *The Journal of Laryngology and Otology*. 2011 01;125(1):3-9. <https://doi.org/10.1017/S0022215110002070>
2. Kleinhans H, Schmid KW, Verse T. Primary squamous cell carcinoma of the thyroid gland. *HNO*. 2013 07;61(7):661-663. <https://doi.org/10.1007/s00106-012-2622-y>
3. Tunio MA, Al Asiri M, Fagih M, Akasha R. Primary squamous cell carcinoma of thyroid: a case report and review of literature. *Head & Neck Oncology*. 2012 03 27;4:8. <https://doi.org/10.1186/1758-3284-4-8>
4. Struller F, Senne M, Falch C, Kirschniak A, Konigsrainer A, Muller S. Primary squamous cell carcinoma of the thyroid: Case report and systematic review of the literature. *International Journal of Surgery Case Reports*. 2017;37:36-40. <https://doi.org/10.1016/j.ijscr.2017.06.011>
5. Lam KY, Lo CY, Liu MC. Primary squamous cell carcinoma of the thyroid gland: an entity with aggressive clinical behaviour and distinctive cytokeratin expression profiles. *Histopathology*. 2001 09;39(3):279-286. <https://doi.org/10.1046/j.1365-2559.2001.01207.x>
6. Ab Hadi I, Bliss RD, Lennard TWJ, Welch AR. Primary squamous cell carcinoma of the thyroid gland: a case report and role of radiotherapy. *The Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland*. 2007 08;5(4):249-251. [https://doi.org/10.1016/s1479-666x\(07\)80010-2](https://doi.org/10.1016/s1479-666x(07)80010-2)
7. Agrawal R, Tandon V, Agrawal A, Agrawal G, Krishnani N, Mishra SK. Squamous cell carcinoma of thyroid gland. *The Journal of the Association of Physicians of India*. 2001 02;49:279-280.
8. Shrestha M, Sridhara SK, Leo LJ, Coppit GL, Ehrhardt NM. Primary squamous cell carcinoma of the thyroid gland: a case report and review. *Head & Neck*. 2013 Oct;35(10):E299-303. <https://doi.org/10.1002/hed.23152>
9. Sun B, Yu S, Ge J, Lei S. Primary squamous cell carcinoma (PSCC) of the thyroid: a case report and review of the literature. *Gland Surgery*. 2020 04;9(2):474-477. <https://doi.org/10.21037/gs.2020.02.18>
10. Cook AM, Vini L, Harmer C. Squamous cell carcinoma of the thyroid: outcome of treatment in 16 patients. *European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology*. 1999 Dec;25(6):606-609. <https://doi.org/10.1053/ejso.1999.0715>
11. Au JK, Alonso J, Kuan EC, Arshi A, St John MA. Primary Squamous Cell Carcinoma of the Thyroid: A Population-Based Analysis. *Otolaryngology--Head and Neck Surgery: Official Journal of American Academy of Otolaryngology-*

- Head and Neck Surgery. 2017 07;157(1):25-29. <https://doi.org/10.1177/0194599817698436>
12. Simpson WJ, Carruthers J. Squamous cell carcinoma of the thyroid gland. American Journal of Surgery. 1988 07;156(1):44-46. [https://doi.org/10.1016/s0002-9610\(88\)80169-7](https://doi.org/10.1016/s0002-9610(88)80169-7)
 13. Tahara M, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, Toda K, et al. Lenvatinib for Anaplastic Thyroid Cancer. Frontiers in Oncology. 2017;7:25. <https://doi.org/10.3389/fonc.2017.00025>
 14. Iñiguez-Ariza NM, Ryder MM, Hilger CR, Bible KC. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer. Thyroid: Official Journal of the American Thyroid Association. 2017 07;27(7):923-927. <https://doi.org/10.1089/thy.2016.0627>
 15. Oishi K, Takabatake D, Shibuya Y. Efficacy of lenvatinib in a patient with anaplastic thyroid cancer. Endocrinology, Diabetes & Metabolism Case Reports. 2017;2017:16-0136. <https://doi.org/10.1530/EDM-16-0136>



This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.